1. Home
  2. BBW vs OMER Comparison

BBW vs OMER Comparison

Compare BBW & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Build-A-Bear Workshop Inc.

BBW

Build-A-Bear Workshop Inc.

HOLD

Current Price

$63.49

Market Cap

696.0M

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$13.52

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBW
OMER
Founded
1997
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
696.0M
628.9M
IPO Year
2004
2009

Fundamental Metrics

Financial Performance
Metric
BBW
OMER
Price
$63.49
$13.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$67.71
$27.50
AVG Volume (30 Days)
443.1K
3.5M
Earning Date
12-04-2025
11-13-2025
Dividend Yield
1.40%
N/A
EPS Growth
15.02
N/A
EPS
4.36
N/A
Revenue
$525,767,000.00
N/A
Revenue This Year
$8.05
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
$14.46
N/A
Revenue Growth
6.17
N/A
52 Week Low
$32.55
$2.95
52 Week High
$75.85
$17.65

Technical Indicators

Market Signals
Indicator
BBW
OMER
Relative Strength Index (RSI) 68.46 58.02
Support Level $58.69 $8.60
Resistance Level $66.17 $17.63
Average True Range (ATR) 2.61 1.33
MACD 0.75 0.30
Stochastic Oscillator 80.66 60.02

Price Performance

Historical Comparison
BBW
OMER

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: